BiotechTube
Home/Pipeline/iPSC-CM Cell Therapy

iPSC-CM Cell Therapy

Cardiovascular Disease

ResearchActive

Key Facts

Indication
Cardiovascular Disease
Phase
Research
Status
Active
Company
Khloris Biosciences

About Khloris Biosciences

Khloris Biosciences is a private, pre-clinical stage biotech developing first-in-class iPSC-based cancer vaccines and cell therapies. The company's platform leverages a large, diverse biobank of human iPSC lines to create vaccines designed to elicit a broad anti-tumor immune response. Khloris has established a key strategic collaboration with Leaps by Bayer, Bayer's investment arm, to advance its anti-cancer vaccine programs, positioning it to address significant unmet needs in oncology and cardiology.

View full company profile

Therapeutic Areas

OncologyCardiovascular

Other Cardiovascular Disease Drugs

DrugCompanyPhase
Manocept DiagnosticNavidea BiopharmaceuticalsResearch
Undisclosed Therapeutic Program(s)HeartcoR SolutionsPre-clinical
Ramatroban (KAR101)KARE BiosciencesPreclinical
Undisclosed Cardiovascular Device ProgramTransluminal TechnologiesPre-clinical
Clinical Trial IntegrationAktiiaVarious
Cardiovascular Disease StudyArizona Research CenterNot Specified
Cardiovascular Clinical TrialsPanThera BioNot Specified
UndisclosedZecardio TherapeuticsDiscovery/Pre-clinical
HDL/LDL RegulationAlpha-1 BiologicsPre-clinical
Cardiovascular ProgramHelixomerResearch
Undisclosed Cardiovascular PrograminQB8 Medical TechnologiesPre-clinical
Undisclosed Cardiovascular Program(s)Salubris BiotherapeuticsClinical-stage (phase unspecified)